Paratek Pharmaceuticals (NASDAQ:PRTK) Receives New Coverage from Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Paratek Pharmaceuticals (NASDAQ:PRTK) in a research note issued to investors on Saturday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

A number of other equities analysts have also recently commented on PRTK. Jefferies Financial Group cut shares of Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, June 7th. HC Wainwright reaffirmed a “neutral” rating and set a $2.15 target price on shares of Paratek Pharmaceuticals in a research note on Monday, August 7th. Finally, BTIG Research dropped their price objective on shares of Paratek Pharmaceuticals from $24.00 to $5.00 in a research note on Tuesday, May 9th.

Paratek Pharmaceuticals Stock Down 0.9 %

Shares of PRTK stock opened at $2.19 on Friday. The company has a 50 day moving average of $2.20 and a 200-day moving average of $2.06. Paratek Pharmaceuticals has a 12-month low of $1.29 and a 12-month high of $3.65. The firm has a market cap of $125.54 million, a P/E ratio of -1.99 and a beta of 1.70.

Paratek Pharmaceuticals (NASDAQ:PRTK) last released its quarterly earnings data on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.06. The business had revenue of $39.99 million during the quarter, compared to the consensus estimate of $34.63 million. As a group, equities analysts expect that Paratek Pharmaceuticals will post -0.79 EPS for the current year.

Insider Buying and Selling

In other Paratek Pharmaceuticals news, Chairman Michael Bigham sold 31,250 shares of the stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $2.20, for a total transaction of $68,750.00. Following the completion of the transaction, the chairman now owns 1,334,702 shares in the company, valued at $2,936,344.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Evan Loh sold 48,967 shares of the firm’s stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $2.20, for a total value of $107,727.40. Following the sale, the chief executive officer now directly owns 1,327,981 shares in the company, valued at approximately $2,921,558.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Michael Bigham sold 31,250 shares of the firm’s stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $2.20, for a total transaction of $68,750.00. Following the completion of the sale, the chairman now owns 1,334,702 shares in the company, valued at $2,936,344.40. The disclosure for this sale can be found here. Over the last quarter, insiders sold 142,346 shares of company stock worth $313,161. 8.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Paratek Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. ETF Managers Group LLC boosted its stake in Paratek Pharmaceuticals by 32.4% during the 1st quarter. ETF Managers Group LLC now owns 18,339 shares of the specialty pharmaceutical company’s stock worth $47,000 after purchasing an additional 4,490 shares during the last quarter. Baird Financial Group Inc. lifted its position in shares of Paratek Pharmaceuticals by 12.8% during the third quarter. Baird Financial Group Inc. now owns 49,070 shares of the specialty pharmaceutical company’s stock worth $126,000 after purchasing an additional 5,570 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in Paratek Pharmaceuticals by 2.2% in the first quarter. Goldman Sachs Group Inc. now owns 259,942 shares of the specialty pharmaceutical company’s stock valued at $772,000 after acquiring an additional 5,629 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Paratek Pharmaceuticals by 28.9% in the first quarter. JPMorgan Chase & Co. now owns 28,946 shares of the specialty pharmaceutical company’s stock valued at $86,000 after acquiring an additional 6,497 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in Paratek Pharmaceuticals by 5.7% in the first quarter. Charles Schwab Investment Management Inc. now owns 129,672 shares of the specialty pharmaceutical company’s stock valued at $386,000 after acquiring an additional 7,019 shares in the last quarter. Hedge funds and other institutional investors own 53.60% of the company’s stock.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris.